Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma

Recruiting now · Phase 2

Conditions studied: Glioblastoma

In brief

The objective of this clinical trial is to investigate the effects of Salovum®, an egg yolk powder enriched with the endogenous protein antisecretory factor, in participants undergoing diagnostic biopsies for suspected glioblastoma. The primary questions the trial seeks to answer are: * Will Salovum® reduce intratumoral pressure? * Will Salovum® influence the release of inflammatory cytokines from tumor tissue? Additionally, the study will investigate the impact of Salovum® on intratumoral partial oxygen pressure and tumor volume. Researchers will: * Place probes for measuring intratumoral pressure, microdialysis, and partial oxygen pressure during a standard biopsy procedure. * Compare measurements from participants before and during ingestion of Salovum®. Participants will: * Have probes implanted during a surgical biopsy. * Ingest Salovum® 24 to 72 hours after the procedure.

Key facts

Study ID

NCT07364786

Run by

Peter Siesjö

People needed

10

Starts

2024-10-07

Expected to finish

2026-11-01

Last updated by the study team

2026-01-23

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Suspected glioblastoma
• Age 18-75 years
• Planned diagnostic biopsy
• Informed consent of subject

You may not qualify if…

• Known egg yolk allergy

Where it is running

• Department of Neurosurgery, Skane University Hospital — Lund, Sweden (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.